

Comparative Trial Balance as at 30 June 2021

	2021	2021	2020	2020
	\$ Dr	\$ Cr	\$ Dr	\$ Cr
Income				
0550		3,928.03		
0575		122.90		677.38
0620		36,048.00		36,048.00
0650		23.52		
0716.01		14,417.01		13,340.30
0865		511,165.86		
Expenses				
1500	3,060.75		804.00	
1502	1,910.25		1,846.21	
1503	2,743.95		1,200.00	
1504	7,988.95		660.00	
1505			54.00	
1520	259.00			
1984			1,994.80	
1998	4,350.00			
Current Assets				
2000	138,286.33		121,083.21	
2100	19,027.15		2,118.76	
Non Current Assets				
2900	140,716.67		102,170.00	
2901	1,146.20		1,146.20	
2902	467,927.64			
2902.01	465,000.00		465,000.00	
2902.02	2,072.36		2,072.36	
Current Liabilities				
3380		901.80		902.60
3381	785.88		67.06	
3390	6,372.00		5,156.00	
3391	2,116.00			9.00
3392	3,643.00		12,290.00	
3450		500.00		500.00
3499		6,008.00		6,008.00

These financial statements are unaudited. They must be read in conjunction with the attached Accountant's Compilation Report and Notes which form part of these financial statements.

Comparative Trial Balance as at 30 June 2021

	2021 \$ Dr	2021 \$ Cr	2020 \$ Dr	2020 \$ Cr
Non Current Liabilities				
3920 Sundry			600.04	
3960.01 L.Grund Loan		265.65		2,846.65
Equity				
4000.01 Larissa opening balance		694,025.36		701,437.38
4002 Current Year Earnings			43,506.67	
	1,267,406.13	1,267,406.13	761,769.31	761,769.31
Net Profit		545,392.42		43,506.67

These financial statements are unaudited. They must be read in conjunction with the attached Accountant's Compilation Report and Notes which form part of these financial statements.